| bHCG | beta human chorionic gonadotropin |
|---|---|
| CG | cardiography; cardiogreen; choking gas; choriogenic gynecomastia; chorionic gonadotropin; chromogran... |
| CGB | chronic gonadotropin, beta-unit |
| CGT | chorionic gonadotropin; cyclodextrin glucanotransferase |
| FIGD | familial idiopathic gonadotropin deficiency |
| sGnRH | Salmon gonadotropin-releasing hormone |
|---|---|
| GnRH | gonadotropin hormone releasing hormone |
| GAP | gonadotropin-releasing hormone associated peptide |
| HMG/HCG | human menopausal gonadotrophin/human chorionic gonadotropin |
| MGnRH | mammalian gonadotropin-releasing hormone |
| competitive inhibition | <chemistry> Inhibitor that occupies the active site of an enzyme or the binding site of a receptor and prevents the normal substrate or ligand from binding. at sufficiently high concentration of the normal ligand inhibition is lost: the Km is altered by the competitive inhibitor, but the Vmax remains the same. (05 Jan 1998) |
|---|---|
| contact inhibition | The inhibition of continued growth and division of a cell or colony due to physical contact with other cells or colonies. The stopping of continued growth when a certain density of cells has been reached. The momentary stopping of all movement when a mobile cell runs into another cell. (09 Oct 1997) |
| contact inhibition of growth | See: density dependent inhibition. (18 Nov 1997) |
| contact inhibition of movement | Reaction in which the direction of motion of a cell is altered following collision with another cell. In heterologous contacts both cell may respond (mutual inhibition) or only one (nonreciprocal). Type I contact inhibition involves paralysis of the locomotory machinery, Type II is a consequence of adhesive preference for the substratum rather than the dorsal surface of the other cell. (18 Nov 1997) |
| contact inhibition of phagocytosis | Phenomenon described in sheets of kidney epithelial cells that, when confluent, lose their weak phagocytic activity, probably because of a failure of adhesion of particles to the dorsal surface in the absence of ruffles. (18 Nov 1997) |
| haemagglutination inhibition | A variation of the haemagglutination technique. Some viral antigens, when coated on erythrocytes, spontaneously cause agglutination in the absence of antibody. In these situations, the specific antigen-antibody reaction actually prevents the agglutination of reagent RBCs. Haemagglutination inhibition cannot differentiate between isotypes of specific antibodies (IgG, IgA or IgM) although positive haemagglutination inhibition analysis of specimens treated with Staphylococcus aureus Protein A (discussed above under coagglutination) to remove the IgG isotype antibodies has been used to imply the presence of specific IgM antibodies to the specific viral antigen. The crude quantitation of the specific antibodies is possible using serial dilution (titre). (05 Mar 2000) |
| haemagglutination inhibition test | <investigation> A clinical lab test used to detect the presence of a certain haemagglutinating virus or other haemagglutinin antigen based on whether the red blood cells in the sample lose the ability to clump together when the antibody to the virus or other antigen is added to it. If the virus or antigen is present, the antibody kills it and thereby stops it from being able to stick the red blood cells to each other. (09 Oct 1997) |
| haemagglutination inhibition tests | Serologic tests in which a known quantity of antigen is added to the serum prior to the addition of a red cell suspension. Reaction result is expressed as the smallest amount of antigen which causes complete inhibition of haemagglutination. (12 Dec 1998) |
| potassium inhibition | Arrest of the heart in the fully relaxed state as a result of potassium intoxication. (05 Mar 2000) |
| haptenic inhibition | <immunology, molecular biology> Could be considered an isolated epitope: although a hapten (by definition) has an antibody directed against it, the hapten alone will not induce an immune response if injected into an animal, it must be conjugated to a carrier (usually a protein). The hapten constitutes a single antigenic determinant, perhaps the best known example is dinitro phenol (DNP) that can be conjugated to BSA and against which antiDNP antibodies are produced (antibodies to the BSA can be adsorbed out). Because the hapten is monovalent, immune complex formation will be blocked if the soluble hapten is present as well as the hapten carrier conjugate (assuming there is more than one hapten per carrier then an immune precipitate can be formed). Competitive inhibition by the soluble small molecule is sometimes referred to as haptenic inhibition and this term has carried over into lectin mediated haemagglutination where monosaccharides are added to try to block haemagglutination: the blocking sugar defines the specificity of the lectin. (18 Nov 1997) |
| hapten inhibition of precipitation | Inhibition of precipitation that occurs when the precipitin has combined with hapten of the same specificity as the subsequently added antigen. (05 Mar 2000) |
| proactive inhibition | The state or process hypothesised to account for poorer learning rate for elements later in a series as compared to the learning rate for elements coming earlier in a series. (12 Dec 1998) |
| product inhibition | Inhibition of an enzyme activity by a product of the reaction catalyzed by that enzyme. (05 Mar 2000) |
| selective inhibition | <chemistry> Inhibitor that occupies the active site of an enzyme or the binding site of a receptor and prevents the normal substrate or ligand from binding. at sufficiently high concentration of the normal ligand inhibition is lost: the Km is altered by the competitive inhibitor, but the Vmax remains the same. (05 Jan 1998) |
| noncompetitive inhibition | <chemistry> A form of enzyme inhibition which cannot be reversed by increasing the amount of substrate in the reaction. (09 Oct 1997) |